On Dec 8, 2018 Abbott Laboratories (NYSE:ABT) Shorts Strengthened By 9.38%

Abbott Laboratories (NYSE:ABT) Corporate Logo

Big Money Sentiment increased to 0.86 in 2018 Q2. It has change of 0.03, from 2018Q1’s 0.83. The ratio increased due to Abbott Laboratories positioning: 41 sold and 583 reduced. 117 funds amassed holdings and 420 increased holdings. Investors holded 1.22 billion in 2018Q1 but now own 1.23 billion shares or 0.63% more.
S&Co owns 280,380 shs. Webster Financial Bank N A invested in 0.08% or 9,170 shs. Alesco Limited Liability Company has invested 0.01% of its capital in Abbott Laboratories (NYSE:ABT). Cranbrook Wealth Lc holds 0.01% or 580 shs. John G Ullman & Associate holds 2.61% or 226,130 shs. Loeb Ptnrs Corp, a New York-based fund reported 16,400 shs. Jupiter Asset Mgmt Ltd reported 197,980 shs stake. Nj State Employees Deferred Compensation Plan has 0.16% invested in Abbott Laboratories (NYSE:ABT) for 14,354 shs. Atwood And Palmer Inc stated it has 0.03% of its capital in Abbott Laboratories (NYSE:ABT). Glovista Investments Limited Liability Company accumulated 4,446 shs. 33,165 are held by Laurion Mgmt Ltd Partnership. Fragasso Group Inc holds 0.07% or 4,654 shs. Ftb Advsrs Incorporated stated it has 0.24% in Abbott Laboratories (NYSE:ABT). Bender Robert & Assocs, a California-based fund reported 11,371 shs. Ascend holds 0.25% or 87,373 shs in its capital.

Abbott Laboratories registered $30.08 million net activity with 0 insider purchases and 13 insider sales since July 21, 2018. $4.30 million worth of Abbott Laboratories (NYSE:ABT) was sold by Contreras Jaime on Wednesday, August 29. On Friday, September 28 Salvadori Daniel Gesua Sive sold $366,957 worth of Abbott Laboratories (NYSE:ABT) or 5,000 shs. Shares for $127,044 were sold by Bracken Sharon J. On Wednesday, August 29 LANE ANDREW H had sold 9,097 shs worth $610,513. On Wednesday, July 25 64,900 shs were sold by CAPEK JOHN M, worth $4.22 million. On Wednesday, November 28 142,341 shs were sold by WHITE MILES D, worth $10.30M.

Abbott Laboratories (NYSE:ABT) had an increase of its shorted shares by 9.38%. It was issued in December by FINRA the 12.75M shorted shares on ABT. The up change of 9.38% from 11.65 million shares was reported. Abbott Laboratories (NYSE:ABT) has 4.43 million shares average volume. It’ll cost 3 days for ABT to restore its previous position.

ABT is hitting $69.95 during the last trading session, after decreased 2.22%.Abbott Laboratories has 7.95M shares volume, 16.84% up from normal. ABT is uptrending and has moved 28.17% since December 8, 2017. The stock outperformed the S&P 500 by 12.55%.

Abbott Laboratories manufactures and sells health care products worldwide.The firm is worth $122.86 billion. The companyÂ’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals to treat pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; anti-infective clarithromycin; cardiovascular and metabolic products; and influenza vaccines, as well as to regulate physiological rhythm of the colon.140.74 is the P/E ratio. The Company’s Diagnostic Products segment provides immunoassay and clinical chemistry systems; assays used to screen and/or diagnosis cancer, cardiac, drugs of abuse, fertility, infectious diseases, and therapeutic drug monitoring; hematology systems and reagents; diagnostic systems and cartridges; instruments to automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detects and measures infectious agents; genomic tests; informatics and automation solutions; and a suite of informatics tools and professional services.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

In total 10 analysts cover Abbott Laboratories (NYSE:ABT). “Buy” rating has 10, “Sell” are 0, while 0 are “Hold”. 100% are bullish. 11 are the (NYSE:ABT)’s analyst reports since June 27, 2018 according to StockzIntelligence Inc. In Thursday, July 19 report Stifel Nicolaus maintained the stock with “Buy” rating. On Monday, October 8 the rating was maintained by JP Morgan with “Overweight”. On Monday, September 24 the stock has “Outperform” rating by Wells Fargo. On Monday, September 24 the firm has “Outperform” rating given by Raymond James. On Thursday, October 11 the company was maintained by Morgan Stanley. On Thursday, October 18 Raymond James maintained Abbott Laboratories (NYSE:ABT) rating. Raymond James has “Outperform” rating and $79 target. On Friday, November 30 the firm has “Buy” rating by Goldman Sachs given.

For more Abbott Laboratories (NYSE:ABT) news posted briefly go to: Fool.com, Seekingalpha.com, Seekingalpha.com, Nasdaq.com or Fool.com. The titles are as follows: “Stock Market Power Rankings: Save Us, Amazon – The Motley Fool” posted on November 25, 2018, “Medtronic slips 2% premarket on device injuries – Seeking Alpha” on November 26, 2018, “SEC settles insider trading claims against former chief at Advanced Medical Optics – Seeking Alpha” with a publish date: November 13, 2018, “AbbVie Stock Could Become a New Happy Pill for Investors – Nasdaq” and the last “Stock Market Power Rankings: Microsoft Parties Like Its 2002 – The Motley Fool” with publication date: December 02, 2018.

Abbott Laboratories (NYSE:ABT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.